Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cocktail of drugs shows promise for Tough-to-Treat melanoma

NCT ID NCT04417621

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing several combinations of experimental drugs (LXH254, LTT462, trametinib, ribociclib) in 134 people with advanced melanoma that has a BRAF or NRAS mutation and has stopped responding to prior treatment. The main goal is to see if these combinations can shrink tumors. The study is active but no longer recruiting new participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

LXH254, LTT462, trametinib, ribociclib (oral drugs)

What this could lead to

If successful, this could provide new treatment options for people with advanced melanoma that has stopped responding to other therapies.

What could go wrong

This is an early-phase trial with only 134 participants, so results may not apply to everyone. Drug combinations can cause serious side effects, and the cancer may still progress.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous melanoma melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA

Contacts and locations

Locations

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Florida Cancer Specialists

    Fort Myers, Florida, 33901, United States

  • H Lee Moffitt Cancer Center and Research Institute

    Tampa, Florida, 33612, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • Mayo Clinic Mayo Rochester

    Rochester, Minnesota, 55905, United States

  • Mayo Clinic Rochester

    Rochester, Minnesota, 55905, United States

  • Memorial Sloan Kettering

    New York, New York, 10017, United States

  • NYU Laura and Isaac Perlmutter Cancer Center

    New York, New York, 10016, United States

  • Novartis Investigative Site

    CABA, Buenos Aires, C1426ANZ, Argentina

  • Novartis Investigative Site

    North Sydney, New South Wales, 2060, Australia

  • Novartis Investigative Site

    Wooloongabba, Queensland, 4102, Australia

  • Novartis Investigative Site

    Subiaco, Western Australia, 6008, Australia

  • Novartis Investigative Site

    Leuven, 3000, Belgium

  • Novartis Investigative Site

    Wilrijk, 2610, Belgium

  • Novartis Investigative Site

    Lille, 59037, France

  • Novartis Investigative Site

    Marseille, 13885, France

  • Novartis Investigative Site

    Paris, 75475, France

  • Novartis Investigative Site

    Pierre-Bénite, 69495, France

  • Novartis Investigative Site

    Toulouse, 31059, France

  • Novartis Investigative Site

    Villejuif, 94800, France

  • Novartis Investigative Site

    Dresden, Saxony, 01307, Germany

  • Novartis Investigative Site

    Essen, 45147, Germany

  • Novartis Investigative Site

    Heidelberg, 69120, Germany

  • Novartis Investigative Site

    Tübingen, 72076, Germany

  • Novartis Investigative Site

    Ramat Gan, 5265601, Israel

  • Novartis Investigative Site

    Milan, MI, 20133, Italy

  • Novartis Investigative Site

    Naples, 80131, Italy

  • Novartis Investigative Site

    Maastricht, Limburg, 6229 HX, Netherlands

  • Novartis Investigative Site

    Oslo, 0310, Norway

  • Novartis Investigative Site

    Lausanne, 1011, Switzerland

  • Novartis Investigative Site

    Zurich, 8091, Switzerland

  • Novartis Investigative Site

    Manchester, M20 2BX, United Kingdom

  • The Angeles Clinic and Research Institute

    Los Angeles, California, 90025, United States

  • UCSF Medical Center

    San Francisco, California, 94143, United States

  • Univ of TX MD Anderson Cancer Cntr

    Houston, Texas, 77030, United States

  • University of Pittsburgh Med Center

    Pittsburgh, Pennsylvania, 15213, United States